The MCED Inflection Point: What Galleri's FDA Panel Backing Means for Cancer Screening
Dr. Dereck Mush, MD, MBA
Lucence
Develops ultra-sensitive liquid biopsy tests for multi-cancer early detection and profiling.
What they do
Lucence designs and manufactures ultra-sensitive blood tests utilizing proprietary amplicon-based sequencing technology. Clinical oncologists use its LiquidHALLMARK assay to detect cancer mutations with high specificity, helping guide personalized treatment selection and therapeutic monitoring.
The record
- Vertical
- Oncology
- Sub-segment
- Cancer screening and diagnostics
- Product type
- Diagnostics
- Stage
- Series B
- Headquarters
- Singapore
- Region
- Asia-Pacific
- Founded
- 2016
- Total funding
- $29M raised
Notable investors: Luminate Medical, Heliconia Capital Management, Lim Ho Kee.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
The barbershop health screening model is expanding well beyond blood pressure
Dr. Dereck Mush, MD, MBA
Screening Programs Are Rebuilding Around Reminder Systems That Actually Reach People
Dr. Dereck Mush, MD, MBA
PATHFINDER 2 Results: What the Galleri Multi-Cancer Blood Test Actually Found
Dr. Dereck Mush, MD, MBA